Roth W K, Weber M, Seifried E
Institute of Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service, Frankfurt am Main, Germany.
Lancet. 1999 Jan 30;353(9150):359-63. doi: 10.1016/S0140-6736(98)06318-1.
Despite sensitive antibody-based blood-donor screening, a residual risk of transfusion-transmitted viral infections exists. Only direct monitoring by sensitive nucleic-acid tests would provide data accurately to measure the risk and to assess risk-reduction procedures. We investigated the feasibility and efficacy of routine screening of donors for hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV-1 by PCR.
For PCR testing, individual donor plasma samples were pooled (96x100 microL) overnight by two automatic pipetting machines. Viruses were concentrated by centrifugation and nucleic acids were extracted. HCV PCR was done on the Cobas Amplicor system (Hoffmann-La Roche, Mannheim, Germany). HBV and HIV-1 sequences were amplified by single (non-nested) in-house PCRs and detected by agarose-gel electrophoresis. Detection limits were 1000-5000 genome equivalents/mL in the donor blood.
PCR testing was done in parallel to antibody screening with a maximum throughput of 3000 samples in 7-8 h. Positive samples were identified 1-2 days later. 111 of 373,423 donations (107 of 4500 pools) were PCR and antibody/antigen-confirmed positive. We found one HCV PCR-positive antibody-negative donation with normal alanine aminotransferase and one HCV PCR-positive donation with an elevated alanine aminotransferase (100 IU), which was negative in the AxSYM 2.0 and Matrix 1.0, but positive after control in the Abbott Prism test (Abbott GmbH, Wiesbaden, Germany).
PCR is a suitable and fast blood-donor screening procedure and contributes to a reduction in viral transmission by transfusion of blood components. In our selected donor population, the yield of detected contaminated donations from donors in the time window in which they are highly infectious but do not have any symptoms or detectable antigen and antibody concentrations (diagnostic window), confirms theoretical estimates.
尽管基于抗体的献血者筛查较为灵敏,但输血传播病毒感染仍存在残余风险。只有通过灵敏的核酸检测进行直接监测,才能准确提供数据以衡量风险并评估降低风险的程序。我们研究了通过聚合酶链反应(PCR)对献血者进行丙型肝炎病毒(HCV)、乙型肝炎病毒(HBV)和人类免疫缺陷病毒1型(HIV-1)常规筛查的可行性和有效性。
对于PCR检测,通过两台自动移液机将个体献血者血浆样本(96×100微升)混合过夜。通过离心浓缩病毒并提取核酸。HCV PCR在Cobas Amplicor系统(德国曼海姆的霍夫曼-拉罗什公司)上进行。HBV和HIV-1序列通过单重(非巢式)内部PCR扩增,并通过琼脂糖凝胶电泳检测。献血者血液中的检测限为1000 - 5000基因组当量/毫升。
PCR检测与抗体筛查并行进行,最大通量为7 - 8小时检测3000个样本。1 - 2天后鉴定出阳性样本。在373423次献血中有111次(4500个混合样本中有107次)经PCR及抗体/抗原确认呈阳性。我们发现1次HCV PCR阳性但抗体阴性的献血,其丙氨酸转氨酶正常,还有1次HCV PCR阳性的献血丙氨酸转氨酶升高(100国际单位),该样本在AxSYM 2.0和Matrix 1.0检测中呈阴性,但在雅培Prism检测(德国威斯巴登的雅培有限公司)复查后呈阳性。
PCR是一种合适且快速的献血者筛查程序,有助于减少血液成分输血导致的病毒传播。在我们选定的献血者群体中,在高度感染但无症状或无可检测抗原及抗体浓度(诊断窗口期)的时间窗口内,检测到受污染献血的比例证实了理论估计。